Interleukin (IL)-10 is an important immunoregulatory cytokine that mediates its effects via a transmembrane receptor complex consisting of two different chains, IL-10R1 and IL-10R2. While IL-10R2 is ubiquitously expressed and does not bind IL-10 primarily, the expression of IL-10R1 determines cellular responsiveness. However, the current knowledge about the expression and regulation of IL-10R1 is still limited. Here we analyzed the expression of IL-10R1 on monocytic cells and demonstrated that human blood monocytes carried about 720 IL-10-binding sites on their surface. Compared with lymphocytes and various tissue cells and tissues, blood monocytes expressed the highest IL-10R1 levels. The in vitro differentiation of these cells into macrophages provoked a further increase of IL-10R1 surface expression. In contrast, their differentiation into myeloid dendritic cells (mDCs) resulted in reduced surface IL-10R1 levels. The different IL-10R1 levels expressed by monocyte-derived antigen-presenting cell populations were reflected in their different responsiveness toward IL-10. Importantly, also in vivo developed immature macrophages and mDCs showed different IL-10 sensitivity. These data suggest that, compared with monocytes and macrophages, mDCs partially escape from IL-10's inhibitory mechanisms by downregulating IL-10R1.
INTRODUCTION
Interleukin (IL)-10 is a member of the IL-10-interferon cytokine family and one of the most crucial suppressors and regulators of the immune system. 1 Its importance was impressively demonstrated by in vivo situations, which are associated with IL-10 deficiency or excess. In fact, IL-10-deficient mice in infection models show a severe immunopathology as a result of uncontrolled inflammation. 2,3 Furthermore, those mice died from severe chronic enterocolitis due to an unrestrained immune response to food and gut antigens. 4 Accordingly, inborn weakening of IL-10 signaling is associated with inflammatory bowel disease in humans. 5 On the other hand, massive systemic release of IL-10 is critical in the pathogenesis of life-threatening immunodeficiency, which frequently develops in patients after septic shock, trauma, neuroendocrine stress or with certain tumors. [6] [7] [8] Furthermore, IL-10 overproduction is associated with chronic diseases characterized by autoantibody production, such as lupus erythematosus. 9, 10 Blood monocytes are highly sensitive toward IL-10. 1 By acting on these cells, IL-10 regulates both innate and adaptive immune responses by using different mechanisms: First, IL-10 counteracts the activation-induced production of pro-inflammatory cytokines and chemokines and induces the expression of anti-inflammatory mediators of these cells. 1, 11 Second, it inhibits their antigenpresenting capacity by downregulating surface expression of major histocompartibility complex class II and accessory molecules. 1 Third, it increases the monocyte uptake of bacteria and apoptotic cells, thereby favoring their scavenger activity. 12 Monocytes, however, are not terminally differentiated cells. Within 2 days, they move from the blood into stromal tissue where they further differentiate into more specialized cell populations. Dependent on the micromilieu, they either develop into macrophages or myeloid dendritic cells (mDCs). 13 Macrophages are resident cells in many types of tissue where they are specialized as scavenger cells with pro-and anti-inflammatory properties but have limited capacities in terms of adaptive immune responses. 14 mDCs have a high capacity for antigen uptake as long as they are immature. Their activation induces maturation, which is characterized by high expression of major histocompartibility complex class II and co-stimulatory molecules on their surfaces as well as production of soluble molecules. These features enable these cells to highly efficiently stimulate even naive T cells. 15 IL-10 exerts its biological effects by interacting with a transmembrane receptor complex that is composed of two different receptor chains, IL-10R1 and IL-10R2. 16, 17 Both subunits belong to the class II cytokine receptor family. 18 While IL-10R2 is unable to bind IL-10 alone, IL-10R1 has a central role in IL-10 binding and signaling. It (i) is responsible for the initial binding of IL-10, (ii) has a substantial role in stabilizing the IL-10/IL-10R1/ IL-10R2 complex, and (iii) interacts with specific transcription factors. 16, 17, [19] [20] [21] [22] [23] Activation of the IL-10 receptor complex results in signaling pathways, which involve members of the Janus tyrosine kinase family and of the signal transducers and activators of transcription family. 22, 23 Interestingly, IL-10R2, which is widely and strongly expressed in most cells, 24 has turned out to be also a part of the receptor complexes for further members of IL- 10-interferon  cytokine family: IL-22, 25 IL-26, 26 IL-28A, IL-28B, and IL-29. 27 However, the IL-10R2 sharing does not appear to be associated with binding competition for IL-10R2 or mutual limitation of the biological effects of the different mediators. 28 As little is known about the expression and regulation of IL-10R1, we analyzed IL-10R1 in blood monocytes and monocytederived antigen-presenting cells (APCs), cells supposed to represent the main targets of IL-10.
RESULTS

Blood monocytes show high IL-10R1 expression
Monocytic cells appear to be major targets of IL-10 in vivo. We therefore investigated their IL-10R1 expression in comparison to other cell types. The measurement of IL-10R1 gene expression in human blood monocytes and CD4+ naive T cells by real-time PCR revealed a twofold higher expression in monocytes ( Figure 1a ). Blood monocytes expressed also higher IL-10R2 levels than CD4+ T cells. Importantly, as demonstrated for skin-derived cells, including epidermal keratinocytes, dermal fibroblasts, dermal microvascular endothelial cells, subcutaneous adipocytes and melanocytes, no IL-10R1 mRNA expression was found in the different tissue cell populations isolated from a chosen organ ( Figure 1b ). Moreover, when studying human tissues, mostly those containing a large proportion of myeloid cells (such as the spleen, liver, thymus) showed clear IL-10R1 expression ( Figure 1c ). Here the highest expression was observed in the spleen, which, however, was~20-fold lower than the mean human monocyte expression.
We next studied monocyte IL-10R1 surface expression by indirect cell surface staining using an IL-10R1-specific monoclonal antibody (mAb). Specific binding of this mAb was proven by preincubation with an approximately 10-fold molar excess of IL-10. As shown in Figure 1d , monocytes clearly expressed IL-10R1 at the cell surface. In line with mRNA results, low specific staining was detected in lymphocytes.
The high IL-10R1 expression in monocytes was further reflected by a relatively high number of IL-10-binding sites on these cells, which was estimated to be 723 ± 57 sites per cell by means of scatchard-plot analysis (Figures 2a and b ).
Monocyte differentiation is associated with altered IL-10R1 expression Next, we investigated whether cytokines known to promote differentiation of monocytes into functionally distinct subsets 29 alter monocytic IL-10R1 expression. In a kinetic study, peripheral blood mononuclear cells (PBMCs) were cultured in the presence of monocyte colony-stimulating factor (M-CSF), IL-4, granulocyte/ macrophage colony-stimulating factor (GM-CSF) or without stimulation for different time periods. M-CSF, which drives monocytes toward macrophage development, caused a slight and delayed upregulation of IL-10R1 expression, becoming evident after 72 h ( Figure 3a ). In contrast, IL-4 and GM-CSF, which are essential for monocyte differentiation toward mDCs, downregulated monocytic IL-10R1 surface expression. In both the cases, downregulation became evident already after 24 h and remained clearly reduced during the rest of the 72-h test period.
We then tested the dose-dependency of the cytokine-induced modulations of monocytic IL-10R1 expression. PBMCs were treated either with or without M-CSF for 60 h, or with or without IL-4 or GM-CSF, for 36 h. The late time point for the M-CSF study was chosen because of the delayed modulation of monocyte IL-10R1 expression in response to this cytokine (see Figure 3a ). As shown in Figure 3b , monocytic IL-10R1 expression was dose-dependently upregulated by M-CSF and downregulated by IL-4 or GM-CSF. Interestingly, when applied in combination, the effects of IL-4 and GM-CSF on surface IL-10R1 expression were additive (data not shown).
Next we cultured PBMCs with M-CSF and IL-4/GM-CSF for up to 7 days. The following flow cytometric analysis of lineage-specific phenotypes confirmed the development of macrophages (upregulation of CD14 expression) by M-CSF and the development of mDCs (downregulation of CD14 expression, upregulation of CD1a and CD83 expression) by IL-4/GM-CSF and revealed high and low IL-10R1 surface levels on macrophages and mDCs, respectively (Figure 3c ).
Monocytes and monocyte-derived macrophages and mDCs show different IL-10 responsiveness Subsequently, we analyzed whether the observed cytokineinduced modulation of IL-10R1 expression in monocytic cells resulted in a differential IL-10 responsiveness. Monocytes were cultured in the presence of either M-CSF or IL-4/GM-CSF for 72 h followed by washing and re-culture with different doses of IL-10. After 1 and 24 h, bacterial lipopolysaccharide-induced tumor necrosis factor (TNF)-α release (1 h) and human leukocyte antigen (HLA)-DR expression (24 h) were assessed. As indicated in Figure 4 , IL-10 dose-dependently reduced both TNF-α production capacity ( Figure 4a ) and HLA-DR expression ( Figure 4b ) in M-CSFpretreated cells but was much less potent in doing so in IL-4/ GM-CSF-pretreated cells (Figures 4a and b ).
Finally, responsiveness toward IL-10 was investigated in analogous, in vivo-developed APC populations. Freshly isolated PBMCs were cultured with different doses of IL-10 for 12 and 24 h and were subsequently analyzed by flow cytometry. Containing blood mDCs were identified based on the absence of linage markers and the presence of CD11c (Figure 5a ), whereas immature macrophages were identified by lower CD14 expression compared with monocytes. 30 As presented in Figure 5b , increasing IL-10 concentrations induced strong downregulation of HLA-DR expression in immature macrophages and monocytes but had no such effect on mDCs.
DISCUSSION
IL-10 is one of the most important regulators in the immune system, and besides its anti-inflammatory effects, it has an important role in regulating specific cellular immune responses. 1, 31 It exerts its biological effects by interacting with a specific cell surface receptor composed of the IL-10R1 and the IL-10R2 receptor chain. Although IL-10R1 is critical for IL-10 binding and signaling, little is known so far about its expression and regulation in IL-10's major target cells, the monocytic cells. This may be due to the difficult detection of the receptor owing to its low expression levels. For instance, the number of cell surface receptors on individual natural killer cells and B-cell-derived leukemia cells was estimated to be only approximately 90 and 130, respectively, 32, 33 and activation of natural killer, B and T cells is associated with downregulation of IL-10R mRNA expression. 34, 35 By using a two-step staining protocol for flow cytometric detection of cell surface antigen levels, scatchard-plot analysis, and real-time RT-PCR, we were able to analyze IL-10R1 expression and regulation in monocytic cells. Our data demonstrate that blood monocytes express high IL-10R1 levels compared with all other cell types and tissues tested. This was also reflected in the number of IL-10-binding sites per monocyte, which was estimated to be about 720 and therefore exceeds that known from other blood cell subpopulations (see above). Importantly, in vitro differentiation of monocytes into either macrophages or mDCs altered IL-10R1 expression, resulting in even higher levels in macrophages and in downregulated levels in mDCs. This was paralleled by respectively modified responsiveness toward IL-10. Similar to the in vitro situation, different IL-10 responsiveness was also observed between in vivo-developed macrophages and mDCs (from peripheral blood). However, this does not necessarily mean that mDCs completely escape from IL-10's inhibitory actions. In fact, a couple of results indicated at least a slight modulation of DC functions by IL-10. 36, 37 The reduced IL-10 responsiveness of mDCs may contribute to the long half-life of antigen presented by mature mDCs, which was reported to be up to 100 h. 38 Furthermore, our observation that different APCs show different strengths of IL-10 responsiveness proposes the use of different APC populations in different IL-10R1 expression in antigen-presenting cells clinical situation. The application of IL-10-sensitive APCs (like macrophages) may be effective for tolerance induction because the IL-10-induced changes of APC function are essential in this regard. 39 Accordingly, reduced IL-10 sensitivity of mDCs may be responsible for failure of exogenously administered IL-10 to restrain established immune responses. This could at least partially explain the rather moderate effects of IL-10 therapy in patients with rheumatoid arthritis, Crohn's disease and psoriasis. 1 On the other hand, APCs with reduced IL-10 sensitivity may be helpful in situations where an adaptive immune response is needed and where high IL-10 and TGF-β levels are present. 8, 40 Indeed, mDCs are very effective in generating an adaptive immune response, 41 and vaccination therapy with antigen-pulsed mDCs is a promising approach in cancer therapy and anti-microbial immunization. [42] [43] [44] 
MATERIALS AND METHODS
Cell preparation, cell culture and cytokine treatment
PBMCs were isolated from the venous blood of healthy volunteers and cultured as described previously. 45, 46 For IL-10R1 gene expression analysis and IL-10 scatchard-plot binding assays, monocytic and naive CD4+ T cells were separated from PBMCs using the commercially available separation kits (MACS System; Miltenyi Biotec, Bergisch-Gladbach, Germany). These isolated populations were 495% pure as judged by flow cytometric analysis. To study the regulation of monocytic IL-10R1 expression, PBMCs were incubated either without additives or with the following recombinant human cytokines: M-CSF (R&D Systems, Wiesbaden-Nordenstadt, Germany), IL-4 (Pepro Tech Inc., Rocky Hill, SC, USA), GM-CSF (Genzyme, Munich, Germany) or a combination of IL-4 and GM-CSF. Unless stated otherwise, these cytokines were used at 10 ng ml − 1 , and the incubation times were 60 h (M-CSF stimulation) and 36 h (GM-CSF/IL-4 stimulation). For functional analysis of differentiation-associated modulation of IL-10R1 expression, PBMCs were cultured for 3 days with M-CSF or IL-4/GM-CSF, each at 1 ng ml − 1 , washed and re-cultured in the presence of IL-10 (R&D Systems) at 0, 0.25, 0.5, 1 or 2 ng ml − 1 . For assaying the modulation of lipopolysaccharide-induced cytokine release, lipopolysaccharide (100 ngml − 1 ; Escherichia coli 0127 B8; Sigma-Aldrich Chemie, Deisenhofen, Germany) was added after 1 h, and 3 h afterwards culture supernatants were recovered for TNF-α measurement. For assessing the modulation of HLA-DR expression, flow cytometric analysis was performed after 24 h of IL-10 stimulation. For assessing IL-10 responsiveness of the different in vivo-generated monocytic APC populations, PBMCs were cultured with 0, 0.25, 0.5, 1 or 2 ng ml − 1 IL-10 for 12 and 24 h followed by flow cytometric analysis of HLA-DR expression by the respectively gated cell populations.
Primary human epidermal keratinocytes and dermal fibroblasts were obtained from Lonza (Vervier, Belgium) and cultured as described previously. 24 Adipocytes were generated from primary human subcutaneous preadipocytes (Lonza) by culturing them for 10 days with PGM-2 differentiation medium (Lonza). Primary human dermal microvascular endothelial cells and melanocytes were purchased from Invitrogen (Karlsruhe, Germany) and cultured as described previously. 47, 48 Gene expression analysis Total RNA was isolated from monocytic and naive CD4+ T cells using the Total RNA isolation reagent (Advanced Biotechnologies, Epsom, UK). Human total RNA panels from different tissues were obtained from Clontech Laboratories (Heidelberg, Germany). Removal of contaminating genomic DNA and reverse transcription were performed using RQ1 DNase (Promega, Mannheim, Germany) and moloney murine leukemia virus reverse transcriptase (Gibco BRL, Eggenstein, Germany). The expression of IL-10R1, IL-10R2 and of the housekeeping gene hypoxanthine phosphoribosyltransferase-1 (HPRT-1) was analyzed in triplicates by TaqMan PCR (ABI Prism 7700 Sequence Detector and Stepone plus devices; Applied Biosystems, Weiterstadt, Germany) as described previously. [49] [50] [51] The following PCR primers and fluorochrome-labeled oligonucleotide probes were used: 5′-GCATCTTCAGTCACTTCCGAGAG-3′, 5′-ATGGTTTCACCTGGACACAGAAC-3′, 6-carboxy-fluorescein (FAM)-5′-ATG AGATTGCCATTCGCAAGGTGCC-3′-6-carboxy-tetramethyl-rhodamine (TAMRA) (IL-10R1); 5′-GAGTGAGCCTGTCTGTGAGCAA-3′, 5′-TGACGGCCACCATCCAG-3′, FAM-5′-CAACCCATGACGAAACGGTCCCCT-3′-TAMRA (IL-10R2); and 5′-GGC TTATATCCAACACTTCG-3′, 5′-GACTTTGCTTTCCTTGGTCAGG-3′, FAM-5′-T TTCACCAGCAAGCTTCGACCTTGA-3′-TAMRA (HPRT-1). Control experiments demonstrated similar amplification efficiencies for IL-10R1, IL-10R2 and HPRT-1 sequences.
Scatchard-plot binding assay
Monocytes (25 million ml − 1 ) were incubated with 200-4500 pM of 125 Ilabeled IL-10 (NEN LifeScience Products, Boston, MA, USA) in the presence or absence of a 100-fold molar excess of unlabeled IL-10 (NEN LifeScience Products) at 4°C for 2 h. Afterwards, cells were washed, layered over a 1:1 mixture of dibutyl-and dioctylphthalate oils (both from Sigma-Aldrich Chemie), centrifuged at 300 g for 5 min and quickly frozen. The cell pellets were then cut and analyzed by means of a γ-counter (1470 Wizard; Perkin-Elmer Cetus). Specific binding of 125 I-labeled IL-10 was defined as the difference between counts per minute (cpm) obtained in the absence and in the presence of unlabeled IL-10. The number of IL-10-binding sites per cell was calculated using linear regression considering the number of monocytes and a stoichiometrical receptor binding of the dimeric IL-10 molecule.
Flow cytometric analysis
To quantify IL-10R1 cell surface expression, we used a two-step staining protocol for flow cytometric detection, which leads to an approximately 10-fold amplification of the specific fluorescence signal compared with direct staining. In detail, PBMCs were incubated with 5 μg ml − 1 of a nonconjugated mAb against IL-10R1 (37607.11) or a respective isotype control (11711.11) (both from R&D Systems) at 4°C for 20 min. After washing, cells were incubated with R-phycoerythrin (PE)-labeled goat anti-mouse IgG (H,L) F(ab') 2 fragment (16.6 μg ml − 1 ; Jackson ImmunoResearch Laboratories, West Groove, PA, USA) at 4°C for 20 min followed by flow cytometric analysis of antibody binding to monocytic and lymphocytic cells gated based on their scatter properties. For verification of specific staining, cells were preincubated with IL-10 (5 μg ml − 1 ) for 30 min at 4°C before addition of the primary mAb. Data are given as the mean fluorescence intensity (MFI) of the target cell population after staining with anti-IL-10R1 mAb and after staining with the respective isotype control.
For verification of monocyte gating, a separate sample was stained each time in parallel with PE-anti-CD14 mAb (RMO52; Coulter Immunotech, Hamburg, Germany). For analysing the IL-10 response of mDCs, cells were stained with Lineage cocktail 1 consisting of fluorescein isothiocyanate (FITC)-labeled mAbs against CD3 (SK7), CD14 (MϕP9), CD16 (3G8), CD19 (SJ25C1), CD20 (L27) and CD56 (NCAM16.2) and with allophycocyanin (APC)-labeled anti-CD11c mAb (S-HCL-3) (all from Becton Dickinson, Heidelberg, Germany). The proportion of gated mDCs (absence of linage antigens, CD11c+) varied between 0.1% and 0.6% of PBMCs. Furthermore, in this study the following mAbs were used according to the manufacturer's protocol: FITC-anti-CD14 (RMO52), FITCanti-CD16 (3G8), FITC-anti-CD83 (HB15A), PE-anti-CD1a (BL6), PE-anti-CD19 (J4.119) (all from Coulter Immunotech); and PE-anti-HLA-DR (L243), mouse PE-IgG2a (X39), peridinin chlorophyll protein (PerCP)-labeled anti-CD3 (SK7) and APC-anti-CD14 (MϕP9) (all from Becton Dickinson). The flow cytometric analysis was performed using a FACSort instrument with LYSYS II software (Becton Dickinson). About 30 000 PBMCs per measurement were analyzed, with the exception of in vivo-developed dendritic cells, where about 500 000 PBMCs were measured.
TNF-α quantification
Detection of TNF-α concentrations in culture supernatants was realized using the Immulite automated ELISA (DPC Biermann, Bad Nauheim, Germany). . Monocyte differentiation into macrophages or mDCs is associated with different IL-10 responsiveness. PBMCs were incubated for 3 days either with M-CSF or a combination of IL-4 and GM-CSF (each at 1 ng ml − 1 ). (a) To assess IL-10-induced modulation of monocyte TNF-α production, PBMCs were re-cultured without (control) or with different doses of IL-10. After 1 h, lipopolysaccharide (100 ng ml − 1 ) was added, and TNF-α production was assessed following another 3-h incubation. Mean data (± s.e.m.) from five independent experiments are given as relative to TNF-α release by control cells, whose TNF-α production was 4542 ±894.9 (M-CSF) and 6408 ± 1922.1 pg ml − 1 (IL-4/GM-CSF), respectively. (b) To assess the IL-10-induced modulation of HLA-DR surface expression, PBMCs were re-cultured without (control) or with different doses of IL-10 for 24 h, and monocyte HLA-DR expression was assessed by flow cytometry. Mean (± s.e.m.) MFI data from five independent experiments are given as relative to HLA-DR expression of control cells, whose expression was 3022.6 ±336.9 (M-CSF) and 1709.9 ± 221.1 (IL-4/GM-CSF), respectively (*P o0.05 for GM-CSF-versus IL-4/GM-CSF-treated cells; Wilcoxon matched-pairs signed-rank test). 
